Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12723446 | 1.00 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL13137591 | 1.00 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL14262857 | 1.00 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL30924343 | 1.00 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL30583390 | 1.00 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL16366105 | 1.00 | MTAP (1.00) | MTAPPNP | |
| Hydrochloric Acid SCHEMBL1222615 | 0.99 | MTAP (1.00) | MTAPPNP | |
| SCHEMBL13464019 | 0.89 | MTAP (0.81) | MTAPPNP | |
| SCHEMBL15593319 | 0.89 | MTAP (0.98) | MTAPPNP | |
| SCHEMBL15593317 | 0.87 | MTAP (0.98) | MTAPPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | claimed |
| EP-2049543-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-04-22 | — | — | EP | claimed |
| US-20090012104-A1 | Inhibitors of 5'-Methylthioadenosine Phosphorylase and 5'-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase | BABU YARLAGADDA S | 2009-01-08 | — | — | US | claimed |
| WO-2008030118-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | claimed |
| US-8383636-B2 | Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-02-26 | — | — | US | disclosed |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | disclosed |
| EP-2049543-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-04-22 | — | — | EP | disclosed |
| US-20090012104-A1 | Inhibitors of 5'-Methylthioadenosine Phosphorylase and 5'-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase | BABU YARLAGADDA S | 2009-01-08 | — | — | US | disclosed |
| WO-2008030118-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012104-A1 | Inhibitors of 5'-Methylthioadenosine Phosphorylase and 5'-Methylthioadenosine/S-Adenosylhomocysteine Nucleosidase | MTAP, TYMP, TPMT | MTAP 1/4885PNP 4/4885 |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | MTAP, PNP, TYMP | MTAP 1/4885PNP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.